To reduce waste, choosing the appropriate format of Aggrastat is important, and is dependent on both the patient’s weight and total infusion duration. This video highlights the different formats that can be utilized to administer Aggrastat.
Indication:
Aggrastat® is indicated to reduce the rate of thrombotic cardiovascular events (combined endpoint of death, myocardial infarction, or refractory ischemia/repeat cardiac procedure) in patients with non-ST elevation acute coronary syndrome (NSTE-ACS).
Contraindications:
Warnings and Precautions:
Adverse Reactions:
For additional information, refer to the full Prescribing Information.
You are encouraged to report negative side effects of prescription drugs to the FDA.
Visit www.FDA.gov/medwatch
or call 1-800-FDA-1088.